Papon Muangsanit

Dr. Papon Muangsanit

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2018 in The Anatomical Record
Verified
Journal Article
Open access
PDF file
PMPapon Muangsanit
Papon Muangsanit
RSRebecca J. Shipley
Rebecca J. Shipley
JPJames B. Phillips
James B. Phillips
Vascularization plays a significant role in treating nerve injury, especially to avoid the central necrosis observed in nerve grafts for large and long nerve defects. It is known that sufficient vascularization can sustain cell survival and maintain cell integration within tissue‐engineered constructs. Several studies have also shown that vascularization affects nerve regeneration. Motivated by these studies, vascularized nerve grafts have been developed using various different techniques, although donor site morbidity and limited nerve supply remain significant drawbacks. Tissue engineering provides an exciting alternative approach to prefabricate vascularized nerve constructs which could overcome the limitations of grafts. In this review article, we focus on the role of vascularization in nerve regeneration, discussing various approaches to generate vascularized nerve constructs and the contribution of tissue engineering and mathematical modeling to aid in developing vascularized engineered nerve constructs, illustrating these aspects with examples from our research experience. Anat Rec, 301:1657–1667, 2018. © 2018 The Authors. The Anatomical Record published by Wiley Periodicals, Inc. on behalf of American Association of Anatomists.

1 May 2021 in Acta Biomaterialia
Verified
Journal Article
Closed access
PMPapon Muangsanit
Papon Muangsanit
VRVictoria Roberton
Victoria Roberton
ECEleni Costa
Eleni Costa
JPJames B. Phillips
James B. Phillips

1 August 2020 in Journal of Neural Engineering
Verified
Journal Article
Open access
PDF file
PMPapon Muangsanit
Papon Muangsanit
ADAdam Day
Adam Day
SDSavvas Dimiou
Savvas Dimiou
AAAltay Frederick Ataç
Altay Frederick Ataç
CKCéline Kayal
Céline Kayal
JPJames B. Phillips
James B. Phillips
Objective. Gel aspiration-ejection (GAE) has recently been developed for the rapid production of dense, anisotropic collagen gel scaffolds with adjustable collagen fibrillar densities. In this study, a GAE system was applied to produce aligned Schwann cells within a type-1 collagen matrix to generate GAE-engineered neural tissues (GAE-EngNT) for potential nerve tissue engineering applications. Approach. The stability and mechanical properties of the constructs were investigated along with the viability, morphology and distribution of Schwann cells. Having established the methodology to construct stable robust Schwann cell-loaded engineered neural tissues using GAE (GAE-EngNTs), the potential of these constructs in supporting and guiding neuronal regeneration, was assessed both in vitro and in vivo. Main results. Dynamic mechanical analysis strain and frequency sweeps revealed that the GAE-EngNT produced via cannula gauge number 16 G (∼1.2 mm diameter) exhibited similar linear viscoelastic behaviors to rat sciatic nerves. The viability and alignment of seeded Schwann cells in GAE-EngNT were maintained over time post GAE, supporting and guiding neuronal growth in vitro with an optimal cell density of 2.0 × 106 cells ml−1. An in vivo test of the GAE-EngNTs implanted within silicone conduits to bridge a 10 mm gap in rat sciatic nerves for 4 weeks revealed that the constructs significantly promoted axonal regeneration and vascularization across the gap, as compared with the empty conduits although less effective regeneration compared with the autograft groups. Significance. Therefore, this is a promising approach for generating anisotropic and robust engineered tissue which can be used with Schwann cells for peripheral nerve repair.

31 January 2024 in Neural Regeneration Research
Verified
Journal Article
Open access
PMPapon Muangsanit
Papon Muangsanit
PSPoppy Smith
Poppy Smith
An abstract is unavailable. This article is available as a PDF only.

6 January 2025 in Tissue Engineering Part B: Reviews
Verified
Journal Article
Closed access
PMPapon Muangsanit
Papon Muangsanit
PYPinyaphat Yuddnaraveesak
Pinyaphat Yuddnaraveesak
WSWeerachai Singhatanadgit
Weerachai Singhatanadgit
The increasing number of elderly people across the globe has led to a rise in osteoporosis and bone fractures, significantly impacting the quality of life and posing substantial health and economic burdens. Despite the development of tissue-engineered bone constructs and stem cell-based therapies to address these challenges, their efficacy is compromised by inadequate vascularization and innervation during bone repair. Innervation plays a pivotal role in tissue regeneration, including bone repair, and various techniques have been developed to fabricate innervated bone scaffolds for clinical use. Incorporating neural-related cells and delivering neurotrophic factors are emerging strategies to accelerate bone regeneration through innervation. However, research into neurogenic cell sources remains limited. Meanwhile, neural stem/progenitor cells (NSPCs) are emerging as promising cells for treating neurodegenerative disorders and spinal cord injuries due to their multifunctional capacity in promoting angiogenesis, neurogenesis, and immunomodulation, making them promising candidates for achieving innervation in bone substitutes. In this review, we discuss the regenerative potential of NSPCs in tissue regeneration. We propose their feasibility for bone therapy through their secreted exosomes during traumatic brain injury, contributing to the acceleration of bone healing. Additionally, we discuss the essential neurotrophic factors released from NSPCs and their osteogenic properties. This review emphasizes the necessity for further investigation of the role of NSPCs in bone regeneration.

10 August 2026 in ACS Omega
Verified
Journal Article
Open access
KNKhin Cho Nyein
Khin Cho Nyein
MGMaxius Gunawan
Maxius Gunawan
PMPapon Muangsanit
Papon Muangsanit
SASudartip Areecheewakul
Sudartip Areecheewakul
JCJittima Chatchawalsaisin
Jittima Chatchawalsaisin
NNNattika Nimmano
Nattika Nimmano
Non-small cell lung cancer (NSCLC), the most common subtype of lung cancer, remains a major contributor to cancer-related mortality worldwide. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, has beenrepurposed as an anticancer agent for NSCLC therapy. In the present study, celecoxib-loaded Soluplus/zein composite nanoparticles coated with chitosan were successfully developed and evaluated as a promising pulmonary drug delivery system for NSCLC. The nanoparticles were prepared using an antisolvent precipitation technique and demonstrated favorable physicochemical properties. The optimized formulation exhibited a particle size of approximately 190 nm with high encapsulation efficiency (85.34%), and high drug-loading capacity (14.21%). The chitosan coating increased the zeta potential to nearly +30.42 mV, yielding enhanced stability and desirable mucoadhesive properties for pulmonary administration. In vitro release studies revealed sustained release under simulated physiological lung conditions, following diffusion- and swelling-controlled release mechanisms. Cytotoxicity evaluation using the MTT assay demonstrated significant anticancer activity against A549 lung cancer cells while maintaining good biocompatibility toward BEAS-2B normal human bronchial epithelial cells. The optimized nanoparticles also showed efficient transport across an air–liquid interface (ALI) airway epithelial barrier, with a Papp value of 4.15 × 10–4 cm·s–1 and 0.38% translocation after 24 h. Furthermore, aerosolized nanoparticles displayed excellent aerodynamic performance, with a fine particle fraction (FPF) of 68.51% and a mass median aerodynamic diameter (MMAD) of 3.93 μm using the Next Generation Impactor (NGI). Overall, these findings highlight the potential of celecoxib-loaded Soluplus/zein nanoparticles coated with chitosan as a promising pulmonary drug delivery system for NSCLC via nebulization.